Enterprise Platform Upsell VarSeq 3 and VSWarehouse 3 offer a scalable, multi-user platform for secondary and tertiary analysis across panels, exomes, and whole genomes from short-read or long-read data. This creates a clear upsell opportunity to mid-sized labs, pharma, and academic customers seeking enterprise collaboration, governance, and richer workflow capabilities.

PGx and Clinical Growth NIH funding of 2.2M highlights demand for pharmacogenomics and clinical-grade interpretation tools. Target clinical labs, biopharma, and hospital systems with PGx decision-support and regulatory-ready analytics, and explore co-development or integration opportunities.

Strategic Partnerships Strategic collaboration with Genomenon to integrate informatics products signals a pathway for joint selling of end-to-end clinical workflows. Propose co-marketing, bundled offerings, and global lab rollout strategies across Golden Helix and partner networks.

Conference Momentum Active participation in major genetics conferences such as ESHG and ACMG signals strong market visibility. Leverage demonstrations of CI-SpliceAI tracks and genome-wide CI-SpliceAI scores to generate enterprise leads and validate product-market fit with researchers and clinicians.

Market Focus Serving pharma, biotech, and academia with genomic data analytics positions Golden Helix in the mid-market for personalized medicine and diagnostics development. Focus account-based selling on mid-size pharma, CROs, and academic consortia for platform adoption and long-term engagements.